APO Research
Talk to an analyst

APO RESEARCH · REPORT

Waldenstrom Macroglobulinemia Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Waldenstrom Macroglobulinemia Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025197 pages

Choose your research edition.

Industry ResearchWaldenstrom Macroglobulinemia Therapeutics Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Waldenstrom Macroglobulinemia Therapeutics Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Waldenstrom Macroglobulinemia Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Waldenstrom Macroglobulinemia Therapeutics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Waldenstrom Macroglobulinemia Therapeutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Waldenstrom Macroglobulinemia Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Waldenstrom Macroglobulinemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Waldenstrom Macroglobulinemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Waldenstrom Macroglobulinemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Waldenstrom Macroglobulinemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Waldenstrom Macroglobulinemia Therapeutics include Merck KGaA, Millennium Pharmaceuticals, Inc., Karyopharm Therapeutics, Inc., Incyte Corporation, IGF Oncology, LLC., Idera Pharmaceuticals, Inc., Hutchison MediPharma Limited, Gilead Sciences, Inc. and Genmab A/S, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Waldenstrom Macroglobulinemia Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Waldenstrom Macroglobulinemia Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Waldenstrom Macroglobulinemia Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Waldenstrom Macroglobulinemia Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Waldenstrom Macroglobulinemia Therapeutics Segment by Company

Merck KGaA

Millennium Pharmaceuticals, Inc.

Karyopharm Therapeutics, Inc.

Incyte Corporation

IGF Oncology, LLC.

Idera Pharmaceuticals, Inc.

Hutchison MediPharma Limited

Gilead Sciences, Inc.

Genmab A/S

Genentech, Inc.

Celgene Corporation

Calithera Biosciences, Inc.

BeiGene(Beijing) Co.,Ltd

Waldenstrom Macroglobulinemia Therapeutics Segment by Type

CB-839

DI-B4

FV-162

Entospletinib

Copanlisib Hydrochloride

Everolimus

Others

Waldenstrom Macroglobulinemia Therapeutics Segment by Application

Clinic

Hospital

Others

Waldenstrom Macroglobulinemia Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Waldenstrom Macroglobulinemia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Waldenstrom Macroglobulinemia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Waldenstrom Macroglobulinemia Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Waldenstrom Macroglobulinemia Therapeutics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Waldenstrom Macroglobulinemia Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Waldenstrom Macroglobulinemia Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Waldenstrom Macroglobulinemia Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Waldenstrom Macroglobulinemia Therapeutics Industry Trends Table 2. Waldenstrom Macroglobulinemia Therapeutics Industry Drivers Table 3. Waldenstrom Macroglobulinemia Therapeutics Industry Opportunities and Challenges Table 4. Waldenstrom Macroglobulinemia Therapeutics Industry Restraints Table 5. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Manufacturers Table 9. Global Waldenstrom Macroglobulinemia Therapeutics Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Waldenstrom Macroglobulinemia Therapeutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Waldenstrom Macroglobulinemia Therapeutics Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Waldenstrom Macroglobulinemia Therapeutics Manufacturers, Product Type & Application Table 13. Global Waldenstrom Macroglobulinemia Therapeutics Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Waldenstrom Macroglobulinemia Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of CB-839 Table 17. Major Manufacturers of DI-B4 Table 18. Major Manufacturers of FV-162 Table 19. Major Manufacturers of Entospletinib Table 20. Major Manufacturers of Copanlisib Hydrochloride Table 21. Major Manufacturers of Everolimus Table 22. Major Manufacturers of Others Table 23. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 24. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (W Units) Table 25. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2027-2032) & (W Units) Table 26. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Type (2021-2026) Table 27. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Type (2027-2032) Table 28. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 29. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021-2026) & (W Units) Table 30. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2027-2032) & (W Units) Table 31. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Type (2021-2026) Table 32. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Hospital Table 35. Major Manufacturers of Others Table 36. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 37. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (W Units) Table 38. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2027-2032) & (W Units) Table 39. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Application (2021-2026) Table 40. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Application (2027-2032) Table 41. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 42. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021-2026) & (W Units) Table 43. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2027-2032) & (W Units) Table 44. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Application (2021-2026) Table 45. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Application (2027-2032) Table 46. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 47. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region (2021-2026) & (W Units) Table 48. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Region (2021-2026) Table 49. Global Waldenstrom Macroglobulinemia Therapeutics Sales Forecasted by Region (2027-2032) & (W Units) Table 50. Global Waldenstrom Macroglobulinemia Therapeutics Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Waldenstrom Macroglobulinemia Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 52. North America Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026) & (W Units) Table 53. North America Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2027-2032) & (W Units) Table 54. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026) & (W Units) Table 56. Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2027-2032) & (W Units) Table 57. Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026) & (W Units) Table 59. Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2027-2032) & (W Units) Table 60. South America, Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 61. South America, Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026) & (W Units) Table 62. South America, Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2027-2032) & (W Units) Table 63. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Region (2021-2026) Table 67. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Region (2027-2032) Table 68. Merck KGaA Company Information Table 69. Merck KGaA Business Overview Table 70. Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 72. Merck KGaA Recent Development Table 73. Millennium Pharmaceuticals, Inc. Company Information Table 74. Millennium Pharmaceuticals, Inc. Business Overview Table 75. Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 77. Millennium Pharmaceuticals, Inc. Recent Development Table 78. Karyopharm Therapeutics, Inc. Company Information Table 79. Karyopharm Therapeutics, Inc. Business Overview Table 80. Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 82. Karyopharm Therapeutics, Inc. Recent Development Table 83. Incyte Corporation Company Information Table 84. Incyte Corporation Business Overview Table 85. Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 87. Incyte Corporation Recent Development Table 88. IGF Oncology, LLC. Company Information Table 89. IGF Oncology, LLC. Business Overview Table 90. IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 92. IGF Oncology, LLC. Recent Development Table 93. Idera Pharmaceuticals, Inc. Company Information Table 94. Idera Pharmaceuticals, Inc. Business Overview Table 95. Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 97. Idera Pharmaceuticals, Inc. Recent Development Table 98. Hutchison MediPharma Limited Company Information Table 99. Hutchison MediPharma Limited Business Overview Table 100. Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 102. Hutchison MediPharma Limited Recent Development Table 103. Gilead Sciences, Inc. Company Information Table 104. Gilead Sciences, Inc. Business Overview Table 105. Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 107. Gilead Sciences, Inc. Recent Development Table 108. Genmab A/S Company Information Table 109. Genmab A/S Business Overview Table 110. Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 112. Genmab A/S Recent Development Table 113. Genentech, Inc. Company Information Table 114. Genentech, Inc. Business Overview Table 115. Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 117. Genentech, Inc. Recent Development Table 118. Celgene Corporation Company Information Table 119. Celgene Corporation Business Overview Table 120. Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 122. Celgene Corporation Recent Development Table 123. Calithera Biosciences, Inc. Company Information Table 124. Calithera Biosciences, Inc. Business Overview Table 125. Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 127. Calithera Biosciences, Inc. Recent Development Table 128. BeiGene(Beijing) Co.,Ltd Company Information Table 129. BeiGene(Beijing) Co.,Ltd Business Overview Table 130. BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 132. BeiGene(Beijing) Co.,Ltd Recent Development Table 133. Key Raw Materials Table 134. Raw Materials Key Suppliers Table 135. Waldenstrom Macroglobulinemia Therapeutics Distributors List Table 136. Waldenstrom Macroglobulinemia Therapeutics Customers List Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Waldenstrom Macroglobulinemia Therapeutics Product Image Figure 2. Global Waldenstrom Macroglobulinemia Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Waldenstrom Macroglobulinemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Waldenstrom Macroglobulinemia Therapeutics Sales (2021-2032) & (W Units) Figure 5. Global Waldenstrom Macroglobulinemia Therapeutics Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Waldenstrom Macroglobulinemia Therapeutics Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. CB-839 Image Figure 9. DI-B4 Image Figure 10. FV-162 Image Figure 11. Entospletinib Image Figure 12. Copanlisib Hydrochloride Image Figure 13. Everolimus Image Figure 14. Others Image Figure 15. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Type (2021-2032) Figure 18. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 19. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Type (2021-2032) Figure 21. Clinic Image Figure 22. Hospital Image Figure 23. Others Image Figure 24. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Application (2021-2032) Figure 27. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 28. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Application (2021-2032) Figure 30. North America Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 31. North America Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Country (2021-2032) Figure 32. U.S. Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Canada Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Mexico Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Europe Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Country (2021-2032) Figure 37. Germany Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 38. France Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 39. U.K. Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Italy Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Netherlands Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Country (2021-2032) Figure 44. China Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Japan Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 46. South Korea Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 47. Southeast Asia Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 48. India Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 49. Australia Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South America, Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 51. South America, Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Country (2021-2032) Figure 52. Brazil Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 53. South Africa Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Saudi Arabia Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Turkey Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Argentina Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 57. UAE Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Egypt Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Chile Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2032) & (W Units) Figure 60. Global Waldenstrom Macroglobulinemia Therapeutics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Figure 63. North America Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Figure 65. Europe Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Waldenstrom Macroglobulinemia Therapeutics Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Waldenstrom Macroglobulinemia Therapeutics Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • CB-839
  • DI-B4
  • FV-162
  • Entospletinib
  • Copanlisib Hydrochloride
  • Everolimus
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • Karyopharm Therapeutics, Inc.
  • Incyte Corporation
  • IGF Oncology, LLC.
  • Idera Pharmaceuticals, Inc.
  • Hutchison MediPharma Limited
  • Gilead Sciences, Inc.
  • Genmab A/S
  • Genentech, Inc.
  • Celgene Corporation
  • Calithera Biosciences, Inc.
  • BeiGene(Beijing) Co.,Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Waldenstrom Macroglobulinemia Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Waldenstrom Macroglobulinemia Therapeutics Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Waldenstrom Macroglobulinemia Therapeutics Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Waldenstrom Macroglobulinemia Therapeutics Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Waldenstrom Macroglobulinemia Therapeutics Market Dynamics
  1. 2.1 Waldenstrom Macroglobulinemia Therapeutics Industry Trends
  2. 2.2 Waldenstrom Macroglobulinemia Therapeutics Industry Drivers
  3. 2.3 Waldenstrom Macroglobulinemia Therapeutics Industry Opportunities and Challenges
  4. 2.4 Waldenstrom Macroglobulinemia Therapeutics Industry Restraints
3 Waldenstrom Macroglobulinemia Therapeutics Market by Manufacturers
  1. 3.1 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Manufacturers (2021-2026)
  3. 3.3 Global Waldenstrom Macroglobulinemia Therapeutics Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Waldenstrom Macroglobulinemia Therapeutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Waldenstrom Macroglobulinemia Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Waldenstrom Macroglobulinemia Therapeutics Manufacturers, Product Type & Application
  7. 3.7 Global Waldenstrom Macroglobulinemia Therapeutics Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Waldenstrom Macroglobulinemia Therapeutics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Waldenstrom Macroglobulinemia Therapeutics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Waldenstrom Macroglobulinemia Therapeutics Tier 1, Tier 2, and Tier 3
4 Waldenstrom Macroglobulinemia Therapeutics Market by Type
  1. 4.1 Waldenstrom Macroglobulinemia Therapeutics Type Introduction
  2. 4.1.1 CB-839
  3. 4.1.2 DI-B4
  4. 4.1.3 FV-162
  5. 4.1.4 Entospletinib
  6. 4.1.5 Copanlisib Hydrochloride
  7. 4.1.6 Everolimus
  8. 4.1.7 Others
  9. 4.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type
  10. 4.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2032)
  12. 4.2.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Type (2021-2032)
  13. 4.3 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Type
  14. 4.3.1 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021-2032)
  16. 4.3.3 Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Type (2021-2032)
5 Waldenstrom Macroglobulinemia Therapeutics Market by Application
  1. 5.1 Waldenstrom Macroglobulinemia Therapeutics Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application
  6. 5.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2032)
  8. 5.2.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Application (2021-2032)
  9. 5.3 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Application
  10. 5.3.1 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021-2032)
  12. 5.3.3 Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Application (2021-2032)
6 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region
  1. 6.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region (2021-2026)
  4. 6.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Waldenstrom Macroglobulinemia Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Waldenstrom Macroglobulinemia Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Region
  1. 7.1 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Region
  2. 7.1.1 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Region (2021-2026)
  4. 7.1.3 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Region (2027-2032)
  5. 7.1.4 Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032)
  8. 7.2.2 North America Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032)
  11. 7.3.2 Europe Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck KGaA
  2. 8.1.1 Merck KGaA Company Information
  3. 8.1.2 Merck KGaA Business Overview
  4. 8.1.3 Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  6. 8.1.5 Merck KGaA Recent Developments
  7. 8.2 Millennium Pharmaceuticals, Inc.
  8. 8.2.1 Millennium Pharmaceuticals, Inc. Company Information
  9. 8.2.2 Millennium Pharmaceuticals, Inc. Business Overview
  10. 8.2.3 Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  12. 8.2.5 Millennium Pharmaceuticals, Inc. Recent Developments
  13. 8.3 Karyopharm Therapeutics, Inc.
  14. 8.3.1 Karyopharm Therapeutics, Inc. Company Information
  15. 8.3.2 Karyopharm Therapeutics, Inc. Business Overview
  16. 8.3.3 Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  18. 8.3.5 Karyopharm Therapeutics, Inc. Recent Developments
  19. 8.4 Incyte Corporation
  20. 8.4.1 Incyte Corporation Company Information
  21. 8.4.2 Incyte Corporation Business Overview
  22. 8.4.3 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  24. 8.4.5 Incyte Corporation Recent Developments
  25. 8.5 IGF Oncology, LLC.
  26. 8.5.1 IGF Oncology, LLC. Company Information
  27. 8.5.2 IGF Oncology, LLC. Business Overview
  28. 8.5.3 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  30. 8.5.5 IGF Oncology, LLC. Recent Developments
  31. 8.6 Idera Pharmaceuticals, Inc.
  32. 8.6.1 Idera Pharmaceuticals, Inc. Company Information
  33. 8.6.2 Idera Pharmaceuticals, Inc. Business Overview
  34. 8.6.3 Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  36. 8.6.5 Idera Pharmaceuticals, Inc. Recent Developments
  37. 8.7 Hutchison MediPharma Limited
  38. 8.7.1 Hutchison MediPharma Limited Company Information
  39. 8.7.2 Hutchison MediPharma Limited Business Overview
  40. 8.7.3 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  42. 8.7.5 Hutchison MediPharma Limited Recent Developments
  43. 8.8 Gilead Sciences, Inc.
  44. 8.8.1 Gilead Sciences, Inc. Company Information
  45. 8.8.2 Gilead Sciences, Inc. Business Overview
  46. 8.8.3 Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  48. 8.8.5 Gilead Sciences, Inc. Recent Developments
  49. 8.9 Genmab A/S
  50. 8.9.1 Genmab A/S Company Information
  51. 8.9.2 Genmab A/S Business Overview
  52. 8.9.3 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  54. 8.9.5 Genmab A/S Recent Developments
  55. 8.10 Genentech, Inc.
  56. 8.10.1 Genentech, Inc. Company Information
  57. 8.10.2 Genentech, Inc. Business Overview
  58. 8.10.3 Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  60. 8.10.5 Genentech, Inc. Recent Developments
  61. 8.11 Celgene Corporation
  62. 8.11.1 Celgene Corporation Company Information
  63. 8.11.2 Celgene Corporation Business Overview
  64. 8.11.3 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  66. 8.11.5 Celgene Corporation Recent Developments
  67. 8.12 Calithera Biosciences, Inc.
  68. 8.12.1 Calithera Biosciences, Inc. Company Information
  69. 8.12.2 Calithera Biosciences, Inc. Business Overview
  70. 8.12.3 Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  72. 8.12.5 Calithera Biosciences, Inc. Recent Developments
  73. 8.13 BeiGene(Beijing) Co.,Ltd
  74. 8.13.1 BeiGene(Beijing) Co.,Ltd Company Information
  75. 8.13.2 BeiGene(Beijing) Co.,Ltd Business Overview
  76. 8.13.3 BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  78. 8.13.5 BeiGene(Beijing) Co.,Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Waldenstrom Macroglobulinemia Therapeutics Value Chain Analysis
  2. 9.1.1 Waldenstrom Macroglobulinemia Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Waldenstrom Macroglobulinemia Therapeutics Production Mode & Process
  6. 9.2 Waldenstrom Macroglobulinemia Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Waldenstrom Macroglobulinemia Therapeutics Distributors
  9. 9.2.3 Waldenstrom Macroglobulinemia Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst